Products Elbasvir was approved in many countries in 2016 as a fixed-dose combination with the protease inhibitor grazoprevir in film-coated tablet form (Zepatier). Structure and properties Elbasvir (C49H55N9O7, Mr = 882.0 g/mol) Effects Elbasvir (ATC J05AX68) has antiviral properties. The effects are due to binding to the viral protein NS5A (Non-Structural Protein 5A). Unlike other … Elbasvir
Products Ombitasvir was approved in the EU and many countries in 2014 in film-coated tablet form (Viekirax, combination drug). Structure and properties Ombitasvir (C50H67N7O8, Mr = 894.1 g/mol) Effects Ombitasvir (ATC J05AX66) has antiviral properties against HCV virus. The effects are due to binding to the viral protein NS5A (Non-Structural Protein 5A). Unlike other HCV … Ombitasvir
Products Pibrentasvir was approved in the United States, many countries, and the EU in 2017 as a fixed-dose combination with glecaprevir in film-coated tablet form (Maviret). Structure and properties Pibrentasvir (C57H65F5N10O8, Mr = 1113.2 g/mol) exists as a white to slightly yellow crystalline powder. Effects Pibrentasvir has antiviral properties. The effects are due to binding … Pibrentasvir
Products Velpatasvir was approved in 2016 in fixed combination with the HCV polymerase inhibitor sofosbuvir in film-coated tablet form (Epclusa, Gilead). Another fixed combination is Vosevi with sofosbuvir and voxilaprevir. Structure and properties Velpatasvir (C49H54N8O8, Mr = 883.0 g/mol) Effects Velpatasvir has antiviral properties. The effects are due to binding to the viral protein NS5A … Velpatasvir
Products Ledipasvir is approved as a fixed combination with sofosbuvir in the form of film-coated tablets (Harvoni). It was released in many countries in 2014. The high price of the drug is controversial (see Sofosbuvir). Cheaper generics are available in India: MyHep LVIR. Structure and properties Ledipasvir (C49H54F2N8O6, Mr = 888.9 g/mol) is practically insoluble … Ledipasvir
